Erythropoietin Drug Market Share, Size, Forecast 2022 (1)

1
Also known as hematopoietic, erythropoietin drug
is defined as a glycoprotein hormone that
controls erythropoiesis. Erythropoiesis is
defined as the production of red blood cells
(RBC). A new report on the global erythropoietin
drug market, published by Market Research Future
(MRFR), estimates that this market can visualize
expansion at 9.5 CAGR between 2017 and
2023. The most significant market driving factor
for the global Erythropoietin Drug Market is the
increasing prevalence of diseases like cancer and
various renal diseases. The increasing
investment in medical research development
(RD) and introduction of new drugs are also
carrying forward the market growth. Noth just new
drugs but the market is also getting strong due
to the introduction of several new erythropoietin
drug combinations. Other factors contributing to
the global erythropoietin price growth include
different government initiatives for research
and a wider pool of patients being covered due to
the introduction of new drug combinations. Market
Segmentation The global erythropoietin drug
market segmentation encompasses application,
end-user, and product type. MRFRs take on the
market surveys various facets of the market
in-depth. The application-based segmentation of
this market covers the Human Immunodeficiency
Virus (HIV), oncology, renal diseases, and
others. In the context of end-user, the market
has been segmented into hospital and pharmacy.
Regarding product type, the market has been
segmented into biosimilars, first-generation
formulation, and second-generation
formulation. Key Players Big players in the
global erythropoietin drug market 3SBio (China),
Amgen (USA), Biocon (India), Biosidus
(Argentina), Boehringer Ingelheim (USA),
Celltrion Inc. (South Korea), Dahua
Pharmaceutical (China), Emcure Pharmaceuticals
(India), Hoffmann-La Roche (Switzerland),
Hospira (USA), Intas Pharmaceuticals (India),
Johnson Johnson (USA), Kyowa Hakko Kirin
(Japan), LG Life Sciences Ltd. (South Korea), and
Teva Pharmaceutical Industries Ltd.
(Israel). Regional Segmentation A geographical
outlining of the global erythropoietin for sale
covers North America, Europe, Asia Pacific, and
the Middle East Africa (MEA). North America
holds the largest share in the global market due
to continuously increasing number of the cancer
patient, technological advancement in the medical
sector, availability of advanced medical
services, governmental initiatives for research,
and patient suffering from renal diseases in
North America. USA and Canada generate maximum
market revenue in this region. Some of the key
market players are based in the USA. In Europe,
the market is growing primarily due to the same
reasons as in North America. Amendments in
reimbursement policies and the growing healthcare
sector are also contributing to the market
growth. Due to the availability of advanced
medical facilities, Western Europe is a bigger
regional market than Eastern Europe. The most
powerful country-specific markets in Europe are
France, Germany, Italy, Spain, and the UK. An
inspection of the remaining countries in Western
Europe featured in this report speculate the huge
contribution to market revenue from some other
countries in this region with a sizable revenue
from Eastern Europe too.
2

• During the forecast period, the gains for Asia
  Pacific market can rise high, making it the
  fastest- growing regional market. The factors
  benefitting the market growth in this region are
  increased penetration of healthcare services and
  expanding patient population in countries like
  China and India. Moreover, the increased
  government effort to improve healthcare in these
  countries is creating new growth opportunities
  for the market. Other important country-specific
  markets in this region are Australia, Japan, and
  South Korea. An analysis of the remaining
  countries in the Asia Pacific region featured in
  this report estimates the huge contribution to
  market revenue from some other countries.
• The MEA region holds the lowest share in the
  global market due to poor medical facilities and
  lack of skilled professionals.
• Latest Industry News
• GlaxoSmithKline (GSK) has started the marketing
  activities in Japan to launch a new oral drug
  called daprodustat. Daprodustat is meant to cure
  anemia associated with chronic kidney disease
  (CKD), which is caused by a deficiency in
  erythropoietin. Daprodustat is also expected to
  be an alternative to many erythropoiesis-stimulati
  ng agents (ESAs) that are injected into the body
  of the patient. 21 AUG 2019
• About US
• Market Research Future (MRFR) enable customers to
  unravel the complexity of various industries
  through Cooked Research Report (CRR), Half-Cooked
  Research Reports (HCRR), Raw Research Reports
  (3R), Continuous-Feed Research (CFR), and Market
  Research Consulting Services.
• Contact us
• Market Research Future (part of Wantstats
  Research and Media Private Limited), 99 Hudson
  Street,5Th Floor, New York,
• New York 10013